Maastricht Radiation Oncology — CureCurrent

How to interpret these research links

Connected source records

The exact organization name Maastricht Radiation Oncology appears in 54 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials54

Recruiting shown2

Roles1

SourceClinicalTrials.gov

Clinical trials

54 shown

Lab Research Using Mini-tumors to Study Prostate Cancer TreatmentsNCT07004582 · lead sponsor · 2026-03-15

Developing Breast (Cancer) OrganoidsNCT05317221 · lead sponsor · 2022-09-01

Re-induction of a Systemic Immune Response in Metastatic or Locally Recurrent Lung CancerNCT06024941 · lead sponsor · 2024-12-01

Standard of Care Lifestyle Support for Stage III NSCLC PatientsNCT05287971 · lead sponsor · 2023-08-01

The Effect of 360° Virtual Reality Movies on Fear and AnxietyNCT06199050 · lead sponsor · 2023-06-16

Lung Cancer Organoids and Patient Derived Tumor XenograftsNCT05092009 · lead sponsor · 2022-10-05

ACTIVE_NOT_RECRUITING

Spatial Location of Breast Cancer Local Recurrence After MastectomyNCT06130111 · lead sponsor · 2021-09-01

ARtificial Intelligence for Gross Tumour vOlume SegmentationNCT05775068 · lead sponsor · 2021-07-01

Immune Profiling of Stage III Non-small Cell Lung Cancer Patients Treated With Concurrent Chemoradiation and Adjuvant Durvalumab: A Prospective Observational Phase II TrialNCT04432142 · lead sponsor · 2021-04-01

ACTIVE_NOT_RECRUITING

Immune Profiling After HDR in Local Relapsed Prostate CancerNCT04247217 · lead sponsor · 2020-02-19

Re-Induction After Initial Response With Immune Therapy With Radiotherapy in Lung CancerNCT03406468 · lead sponsor · 2019-07-15

Exploratory Study on Therapy for Breath Hold in RadiotherapyNCT03729661 · lead sponsor · 2019-04-18

20K Distributed Learning ChallengeNCT03564457 · lead sponsor · 2018-07-01

Prospective Validation of 3D Dose Metrics as Selection Criteria for Adaptive Radiotherapy in Breast Cancer PatientsNCT03385031 · lead sponsor · 2018-01-01

Prospective Primary Human Lungcancer Organoids to Predict Treatment ResponseNCT04859166 · lead sponsor · 2017-11-15

Radiomics to Identify Patients at Risk for Developing Pneumonitis, Differentiate Immune Checkpoint Inhibitor-induced Pneumonitis From Other Lung Inflammation and Distinguish Tumour Pseudo-progression From Real Tumour GrowthNCT03305380 · lead sponsor · 2017-09-01

Echocardiography for RILI PredictionNCT02501707 · lead sponsor · 2017-04-25

Detection of Circulating Biomarkers of Immunogenic Cell DeathNCT02921854 · lead sponsor · 2017-04-04

DE-CT in Lung Cancer Proton TherapyNCT02844140 · lead sponsor · 2016-09-01

Elderly With Locally Advanced Lung Cancer: Deciding Through Geriatric Assessment on the Optimal Treatment StrategyNCT02284308 · lead sponsor · 2016-07-01

ACTIVE_NOT_RECRUITING

Tumor Hypoxia With HX4 PET in Several DiseasesNCT02584400 · lead sponsor · 2016-05-01

Time Trends in Waiting Times of NSCLC Patients.NCT01946490 · lead sponsor · 2015-12-01

Combination of SABR and L19-IL2 in Patients With Stage IV Lung Cancer (ImmunoSABR)NCT02735850 · lead sponsor · 2015-12-01

Evaluation of a Web-based Decision Aid Tool for Prostate Cancer PatientsNCT03278197 · lead sponsor · 2015-01-01

Analysis of Treatment Outcome and Toxicity in Non-small Cell Lung Cancer Patients Wither-irradiated to a High Dose for Recurrent DiseaseNCT01941303 · lead sponsor · 2014-08-01

Chloroquine as an Anti-autophagic Radiosensitizing Drug in Stage I-III Small Cell Lung CancerNCT01575782 · lead sponsor · 2014-05-01

Influence of the Use of the Diabetic Drug Metformin on the Overall Survival and Treatment-related Toxicity in Advanced Stage Non-small Cell Lung Cancer Patients.NCT02109549 · lead sponsor · 2014-03-01

State of the Art Photon Therapy Versus Particle Therapy for Small Lung Tumors; a Planning Study Based on a Reference Dataset of PatientsNCT02038413 · lead sponsor · 2014-01-01

Photon Versus Particle Therapy for Recurrent Lung Cancer; a Planning Study Based on a Reference Dataset of Patients.NCT02029222 · lead sponsor · 2013-12-01

Rapid Learning for Lung CancerNCT01949259 · lead sponsor · 2013-09-01

Chloroquine as an Anti-Autophagy Drug in Stage IV Small Cell Lung Cancer (SCLC) PatientsNCT00969306 · lead sponsor · 2013-09-01

Usefulness of Blood Biomarkers for Overall Survival in NSCLCNCT01936571 · lead sponsor · 2013-09-01

Hypoxia-guided Radiotherapy With Cisplatin-etoposide in Stage I-III : Small Cell Lung Cancer(SCLC)NCT01210131 · lead sponsor · 2013-07-01

SDC for Lung Cancer Patients Treated With Curative Primary or Postoperative Radiotherapy or ChemoradiationNCT01855191 · lead sponsor · 2013-06-01

Outpatient Clinic for Late Outcome for Breast Carcinoma in MAASTRO Clinic.NCT01978756 · lead sponsor · 2013-03-01

Nitroglycerin in Non-small Cell Lung CancerNCT01210378 · lead sponsor · 2011-12-01

Adaptive Radiotherapy in Non-small Cell Lung Cancer (NSCLC)NCT01207063 · lead sponsor · 2011-03-01

Prophylactic Cranial Irradiation (PCI) Cognitive Tests in Non-small Cell Lung Cancer (NSCLC) PatientsNCT01290809 · lead sponsor · 2011-01-01

Radiotherapy After Primary Chemotherapy for BreastcancerNCT01279304 · lead sponsor · 2011-01-01

Radiomics: a Study of Outcome in Lung CancerNCT01302626 · lead sponsor · 2010-03-01

Concurrent and Non-concurrent Chemo-radiotherapy or Radiotherapy Alone With Intensity-modulated Radiotherapy (IMRT) for Non Small Cell Lung Cancer (NSCLC) to an Individualised Mean Lung Dose (MLD)NCT01166204 · lead sponsor · 2009-05-01

Concurrent Chemo-radiotherapy With Intensity-Modulated Radiation Therapy (IMRT) for Limited Disease Small Cell Lung Cancer (LD-SCLC)NCT01166191 · lead sponsor · 2009-05-01

Prophylactic Cranial Irradiation (PCI) vs Observation in Stage III NSCLCNCT01282437 · lead sponsor · 2009-01-01

Predictive Value of FDG-PET-CT Scans for Patients With Lung Cancer Receiving Concurrent Chemo-RadiationNCT00522639 · lead sponsor · 2008-10-01

Pre-operative Contrast Enhanced CT to Improve Delineation of the Tumorbed in Radiotherapy for Breast Cancer.NCT00721058 · lead sponsor · 2008-08-01

Phase I Cetuximab and Concurrent Radio-chemotherapyNCT00522886 · lead sponsor · 2007-04-01

Concurrent Chemo-Radiotherapy for Limited Disease Small Cell Lung Cancer (LD-SCLC) on Basis of FDG-PET-ScansNCT00572923 · lead sponsor · 2006-08-01

Concurrent Chemo-radiation Form NSCLC to a Individualized MLDNCT00572325 · lead sponsor · 2006-08-01

Concurrent and Non-concurrent Chemo-radiotherapy or Radiotherapy Alone for Patients With Oligo-metastatic Stage IV Non-small Cell Lung Cancer (NSCLC)NCT01282450 · lead sponsor · 2006-05-01

Radiotherapy for NSCLC to a Individualized MLDNCT00573040 · lead sponsor · 2005-08-01

Safety Study of Individualised Radiation Dose Determination for Lung Cancer Patients.NCT00181545 · lead sponsor · 2004-12-01

Prone Breast Irradiation for Pendulous BreastsNCT00181363 · lead sponsor · 2003-12-01

Phase II Study of Celecoxib and Concurrent Radiotherapy in Stage II-III NSCLCNCT00181532 · lead sponsor · 2003-05-01

HI-CHART:Feasibility of High-Dose Accelerated Conformal RadiotherapyNCT00181506 · lead sponsor · 2001-12-01

Drugs studied in this sponsor's trials

4 mapped RxNorm concepts

These drug records are connected through ClinicalTrials.gov studies listing Maastricht Radiation Oncology as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.

Most studied mapped drug conceptsDistinct linked trials per RxNorm concept; one trial may study several drugs.

celecoxib1

cetuximab1

chloroquine1

nitroglycerin Transdermal System1

celecoxib RxCUI 140587 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial cetuximab RxCUI 318341 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial chloroquine RxCUI 2393 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial nitroglycerin Transdermal System RxCUI 1805880 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial

Sponsor roles

lead sponsor54

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.